Here’s a round-up of last month’s most traded funds.
The information comes from The Share Centre.
| Position | Fund |
| 1 | CF Woodford Equity Income Fund |
| 2 | Fundsmith Equity Fund |
| 3 | Standard Life Investments Global Absolute Return Strategies Fund |
| 4 | Jupiter Global Managed Income Fund |
| 5 | AXA Framlington Biotech Fund |
| 6 | Legal & General UK Index Trust |
| 7 | Aberdeen Foundation GrowthFund |
| 8 | Invesco High Income Fund |
| 9 | First State Asia Pacific Leaders Fund |
| 10 | Polar Capital Healthcare Opportunities Fund |
Head of investment research at The Share Centre Andy Parsons said: “The CF Woodford Equity Income fund remained popular with investors in June. Both strong and defensively aligned, the legion of loyal followers continues to benefit from a style that is robust, steady and resilient.
“As a fund investing in equities on a global basis, the Fundsmith Equity Income Fund is managed by the highly acclaimed and founder of the business Terry Smith. With the number of holdings generally being between 20 -30 stocks, the underlying portfolio clearly depicts the managers conviction in the highly concentrated portfolio of global names in which he invests.
“The third most popular fund was the Standard Life Investments Global Absolute Return Strategies Fund. An absolute behemoth of a fund in size at over £25bn, the fund seeks to deliver positive returns across all market conditions. Returns are achieved through a combination of traditional investments and more advanced techniques using derivatives.
“With an aim of achieving long-term capital growth, the Jupiter Global Managed Income Fund principally invests through equities on an international basis. The fund mainly comprises of companies considered by the manager to be undervalued, which exhibit favourable growth prospects arising from characteristics such as proven management or strong products or services.
“The fifth most popular fund, was has a real sectorial bias, namely the AXA Framlington Biotech Fund. The fund aims to provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomics and medical industries worldwide. Top holdings for the fund managed by Linden Thompson include Gilead and Biogen.
“The next two most popular funds were both index trackers following the performance of the FTSE All-Share Index, namely the Legal & General UK Index Trust and the Aberdeen Foundation Growth fund.
“An historic stalwart within our top ten, the Invesco High Income Fund aims to provide investors with a high level of income, together with capital growth. Whilst the core of the portfolio will invest primarily in UK companies, the fund does have the ability to invest internationally should the manager deem appropriate.
“The final two funds show investor appetite for a higher degree of risk, initially through the First State Asia Pacific Leaders Fund and then the Polar Capital Healthcare Opportunities. Asia is a region with the lure of potentially higher returns; however investments can be high risk. Fund manager Angus Tulloch is supported by a strong team of specialists who are involved in these markets on a daily basis. Whilst the advances in medical and healthcare technology continue at a rapid pace, the offering will provide investors with a significant geographical exposure to the US given the dominance of this market.”
